Well this probably would’ve been a good week for me to take it easy and enjoy the
holiday. But I just couldn’t stay away! This may not be the longest episode of IPO
This Week, but that’s not a bad thing, if you’re like me that still has some gift
wrapping to do. So for those of you with thoughts of IPOs dancing in your heads, let’s settle
in as we cover all the IPO news for the week of December 21st, 2020.
Welcome to IPO This Week for the week of December 21st. Today, as we do each and every week,
we’ll take a look at the new IPOs coming out, as well as the cover all of the companies
with locked up shares expiring. For anyone new here, my name is Kevin and we talk a lot
about IPOs on this channel…so if you’re into keeping up on newly public companies,
you should definitely consider subscribing. For everyone else, it’s great to have you
back. Now, I’m not gonna lie to you, this is going to be a quick episode this week.
Now that doesn’t mean I’m taking it easy, as you know I put out 4 videos since last
week’s episode. Have you been able to keep up? I mean since our last episode, we’ve
talked about the new stimulus bill, Coinbase and UiPath confidentially filing for IPOs,
Poshmark releasing their public filing, and 2 videos on Palantir. I think it’s fair
to say I’ve been busy….and if you like me upping the amount of content I’ve put
out, I’ll take a thumbs up from you. And if you don’t….well….I’ll still take
a thumbs up…you know, it’s the holidays! Don’t be a Scrooge.
Alright, let’s get into it. So for traditional IPOs, the official calendar looks bare…but
rumor has it that a familiar name for those of you who watch every episode of IPO This
Week know might be coming out. The name of that company is Inhibikase. We had them initially
coming out at the end of October. By like I always say, things are always fluid with
IPOs, so that got delayed and then we had them coming out the week of November 9th.
Well, guess what happened? You got it…they didn’t come out again. And then after that,
they had fallen off my radar. And when I was looking ahead to prepare for this week’s
episode, I still didn’t have them coming out. But then over the weekend, I got a comment
from a viewer saying they were coming out this week…so I checked into it, and while
I’m still not seeing a lot of information out there, I did see that IPOScoops does have
Inhibikase coming out this week with the IPO to be priced on Tuesday with trading then
beginning on Wednesday. So I want to give a shout out to Huan for the comment; I hope
I’m saying your name right. While I’m not holding my breath on them actually coming
out, something about fool me once, shame on you, fool me twice, well you know…but anyways,
I’ll share a little refresher on the company with a little bit of new information added.
Inhibikase focuses on treatments for Parkinson’s Disease and other related neurodevelopmental
disorders. Its lead candidate is named IkT-148009 and is being developed for Parkinson’s and
its associated conditions. The company has filed two Investigational New Drug applications;
one for the treatment of Parkinson’s Disease itself, while the second is for treatment
of gastrointestinal complications that arise as early symptoms of Parkinson’s. The company
expects to begin the first dosing of Parkinson’s patients following the IPO, so they have yet
to begin Stage 1 trials. According to a 2018 market research report by Transparency Market
Research cited on the theStreet.com, the global Parkinson’s Disease therapeutics market
was valued at $2.18 billion in 2016 and is projected to reach $5.24 billion by 2025,
resulting in a forecasted Compound Annual Growth Rate of 11%. And right now, researchers
estimate that Parkinson’s affects around 7 to 10 million people worldwide, with around
1 million of them being US citizens. And then by 2040, the Global Burden of Disease Study
expects the disease to affect 13 million people worldwide by that time.
Now some new information was from a release the company put out earlier this month. On
December 3rd, the day before their last amended filing came out, the company announced an
unexpected finding that what they are trying to develop for Parkinson’s could lead them
to also being able to treat multiple system atrophy which is a rare, degenerative neurological
disorder affecting the body's involuntary functions, such as blood pressure, breathing,
bladder functioning and motor control. Again, although rare, the condition affects potentially
15,000 to 50,000 people in the U.S., it’s extremely debilitating and fatal. So this
news greatly impacts the indications that their candidate could be used for.
As of this time in their development, the company has no products on the market, so
excluding some grants they have received, there is no significant revenue to speak of.
Inhibikase looks to be priced within a proposed range of $10 to $12 and begin trading under
the ticker IKT, again, looking like it could be on Wednesday. What’s interesting from
their initial filing, they’re now offering about a million less shares than they originally
had planned. At the midpoint of the proposed range, the company would net about $12 million
dollars with the majority of the proceeds going to fund their studies.
So that’s Inhibikase; hopefully the third time is a charm.
Let’s now go to companies with locked up shares expiring this week. On Wednesday we
have Agora (API), Akouos (AKUS), Albertsons (ACI), Ebang International (EBON), Fusion
Pharmaceuticals (FUSN), and PolyPid (PYPD). And then on Thursday, we have Amesite (AMST).
Just quickly to go back to Albertsons, it’s hard for me to believe, but this was the first
IPO that I covered on the channel. At the time I was looking at investing in companies
that were benefitting from the pandemic, but the interest in that video sparked the idea
to cover all the IPOs coming out every week. Now Albertson’s stock hasn’t done much
over the last six months as it’s still trading a little lower than its IPO price, but I always
look back on the company as the one that helped propel this channel into the direction it
has turned into, so I’ll always look back fondly on the company.
Alright…so, there you go…a little shorter episode of the show, but I hoped you still
liked it. And if you did, please press that like button. And once again, if you’re new
to the channel or just an occasional visitor, we’d love to have you join the community,
afterall, it’s free, you just need to press that little red subscribe button. And with
that, I’m back to wrapping some gifts….thank you again for watching and, until next time,
have a great day!